SCHEMBL24251985

SCHEMBL24251985

C#Cc1ccc2sc(CC)nc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
MAPK1 P28482 2/20 0.58
GAA P10253 1/20 0.58
TRPV1 Q8NER1 4/20 0.47
DYRK1A Q13627 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.41
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
HDAC6 Q9UBN7 3/20 0.35
HSD17B10 Q99714 2/20 0.34
UBE2T Q9NPD8 1/20 0.34
ASIC3 Q9UHC3 1/20 0.34
PPARA Q07869 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TLR8 Q9NR97 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24251979 0.78 SMN1; SMN2 (0.52) NPC1RAB9AGAATRPV1DYRK1A
SCHEMBL2756574 0.76 NPC1 (0.66) NPC1RAB9AMAPK1GAATRPV1
SCHEMBL10151628 0.76 RAB9A (0.66) NPC1RAB9AMAPK1GAATRPV1
SCHEMBL28015668 0.75 NPC1 (0.63) NPC1RAB9AMAPK1GAATRPV1
SCHEMBL9892808 0.75 LOXL2 (0.70) NPC1RAB9AMAPK1GAATRPV1
SCHEMBL7223517 0.75 NPC1 (0.63) NPC1RAB9AMAPK1GAADYRK1A
SCHEMBL2093548 0.75 NPC1 (0.63) NPC1RAB9AMAPK1GAATRPV1
SCHEMBL31003151 0.75 NPC1 (0.63) NPC1RAB9AMAPK1GAATRPV1
SCHEMBL2947099 0.75 NPC1 (0.63) NPC1RAB9AMAPK1GAATRPV1
SCHEMBL4284343 0.75 NPC1 (0.63) NPC1RAB9AMAPK1GAADYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 US disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 US disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 EP disclosed
WO-2022033532-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF FGFR3, FGFR1, FGFR4 NPC1 2173/4885RAB9A 3048/4885MAPK1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.